Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BCM
is a milk-derived peptide with opiate-like properties which is absorbed through the gastrointestinal mucosa. It has been shown to affect gastrointestinal motility, absorption and secretion. Recently, modulation of the immune system by
BCM
was also reported. In this study we investigated the in vitro effect of
BCM
on the human mucosal immune response as represented by lamina propria lymphocyte (LPL) proliferation. Results show that
BCM
significantly inhibited concanavalin A (ConA) stimulated LPL DNA synthesis.
BCM
also inhibited
ornithine decarboxylase
activity (ODC) in ConA-stimulated LPL. Although
BCM
also inhibited 12-O-tetradecanoyl phorbol-13-acetate (TPA) stimulated LPL DNA synthesis, the degree of inhibition was much lower than in ConA-stimulated LPL. The anti-proliferative effect of
BCM
was reversed by the opiate receptor antagonist, neloxone. Our results suggest that
BCM
may affect the human mucosal immune system, possibly via the opiate receptor.
...
PMID:Beta-casomorphin (BCM) and human colonic lamina propria lymphocyte proliferation. 189 31